[Pulmonary Langerhans cell histiocytosis]

Area of Science:

• Pulmonology
• Oncology
• Immunology

Context:

• Pulmonary Langerhans cell histiocytosis (PLCH) is a rare lung disease.
• It is often associated with smoking, but can also occur as a childhood systemic disease.
• Current diagnostic methods do not distinguish between the reactive and tumor-like forms of PLCH.

Purpose:

• To describe the pathological features of PLCH.
• To highlight the diagnostic markers for Langerhans cells (CD1a and langerin).
• To discuss the clinical management and prognosis of PLCH.

Summary:

• PLCH involves nodular proliferation of Langerhans cells in the lungs, accompanied by eosinophils and bronchial wall destruction.
• The reactive form, often linked to smoking, may improve with smoking cessation.
• High-resolution computed tomography (HRCT) can reveal residual scarring.

Impact:

• Distinguishing between PLCH forms is crucial for appropriate treatment and management.
• Understanding the role of smoking is key to preventing and treating PLCH.
• Further research is needed to develop targeted therapies for PLCH.